Immunization for Ebola virus infection

Author:  ["Ling Xu","Anthony Sanchez","Zhi-Yong Yang","Sherif R. Zaki","Elizabeth G. Nabel","Stuart T. Nichol","Gary J. Nabel"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Infection by Ebola virus causes rapidly progressive, often fatal, symptoms of fever, hemorrhage and hypotension. Previous attempts to elicit protective immunity for this disease have not met with success. We report here that protection against the lethal effects of Ebola virus can be achieved in an animal model by immunizing with plasmids encoding viral proteins. We analyzed immune responses to the viral nucleoprotein (NP) and the secreted or transmembrane forms of the glycoprotein (sGP or GP) and their ability to protect against infection in a guinea pig infection model analogous to the human disease. Protection was achieved and correlated with antibody titer and antigen-specific T-cell responses to sGP or GP. Immunity to Ebola virus can therefore be developed through genetic vaccination and may facilitate efforts to limit the spread of this disease.

Cite this article

Xu, L., Sanchez, A., Yang, ZY. et al. Immunization for Ebola virus infection. Nat Med 4, 37–42 (1998). https://doi.org/10.1038/nm0198-037

View full text

>> Full Text:   Immunization for Ebola virus infection

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2